{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-12T16:28:13.504213+00:00","company":{"ticker":"PETS","cik":1040130,"company_name":"PETMED EXPRESS INC"},"pagination":{"limit":100,"returned":46,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"PetCareRx, Inc.","detail":"merger","count":1,"first_seen":"2023-01-17T23:59:59+00:00","last_seen":"2023-01-17T23:59:59+00:00","evidence_fact_ids":[185812]}]},"facts":[{"fact_type":"earnings_release","fact_key":"62fea84a056e32747ca7e3c5fd1c5d04a0a8b34e","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2026-06-02T20:15:54+00:00","payload":{"eps_text":"$(2.74) per diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss of $57.3 million","period_text":"fiscal year ended March 31, 2026","report_date":"2026-06-02","result_type":"reported_results","revenue_text":"$179.0 million"},"claim":"PETMED EXPRESS INC reported fiscal year ended March 31, 2026 results: revenue $179.0 million, net income Net loss of $57.3 million, EPS $(2.74) per diluted share.","evidence_excerpt":"Net sales of $179.0 million compared to $227.0 million in the prior year, a decrease of 21.1%, primarily driven by a decline in prescription medication sales. • Net loss of $57.3 million, or $(2.74) per diluted share, compared to a net loss of $6.3 million, or $(0.30) per diluted share in the prior year.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001040130-26-000016","anchor_url":"https://secwatch.observer/filing/0001040130-26-000016#claim-62fea84a056e32747ca7e3c5fd1c5d04a0a8b34e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013026000016/0001040130-26-000016-index.htm"},{"fact_type":"earnings_release","fact_key":"6566c41bbc4e1f2ad99223926d25a8964ce2ef51","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2026-06-02T20:15:54+00:00","payload":{"eps_text":"$(0.19) per diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss of $4.1 million","period_text":"fourth quarter ended March 31, 2026","report_date":"2026-06-02","result_type":"reported_results","revenue_text":"$42.8 million"},"claim":"PETMED EXPRESS INC reported fourth quarter ended March 31, 2026 results: revenue $42.8 million, net income Net loss of $4.1 million, EPS $(0.19) per diluted share.","evidence_excerpt":"Net sales of $42.8 million compared to $50.8 million in the prior year period, a decrease of 15.6%, primarily driven by a decline in prescription medication sales. • Net loss of $4.1 million, or $(0.19) per diluted share, compared to a net loss of $11.6 million, or $(0.56) per diluted share, for the prior year period.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001040130-26-000016","anchor_url":"https://secwatch.observer/filing/0001040130-26-000016#claim-6566c41bbc4e1f2ad99223926d25a8964ce2ef51","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013026000016/0001040130-26-000016-index.htm"},{"fact_type":"auditor_change","fact_key":"5dbdaf5dff7b4ed5db507058bf75cd30d57c9e50","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2025-12-29T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Baker Tilly","disagreement_text":null,"effective_date":null,"item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"PETMED EXPRESS INC engaged Baker Tilly as its auditor.","evidence_excerpt":"As previously disclosed in the Original 8-K, the Company engaged Baker Tilly as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2026, beginning with the review of the Company’s consolidated financial statements for the fiscal quarter ending December 31, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001040130-25-000112","anchor_url":"https://secwatch.observer/filing/0001040130-25-000112#claim-5dbdaf5dff7b4ed5db507058bf75cd30d57c9e50","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013025000112/0001040130-25-000112-index.htm"},{"fact_type":"auditor_change","fact_key":"5d750b44a8da9c40af399aa00b47ab51e4d49796","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2025-12-29T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"RSM","disagreement_text":"there were no disagreements, as that term is defined in Item 304(a)(1)(iv) of Regulation S-K, between the Company and RSM on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of RSM, would have caused RSM to make reference to the subject matter of the disagreement in its reports","effective_date":"2025-12-19","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"PETMED EXPRESS INC dismissed RSM as its auditor.","evidence_excerpt":"On December 19, 2025, the Company filed, and RSM completed its interim review of, the Company’s Quarterly Reports on Form 10-Q for the three months ended June 30, 2025, and September 30, 2025. Accordingly, the dismissal of RSM as the Company’s independent registered public accounting firm was effective December 19, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001040130-25-000112","anchor_url":"https://secwatch.observer/filing/0001040130-25-000112#claim-5d750b44a8da9c40af399aa00b47ab51e4d49796","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013025000112/0001040130-25-000112-index.htm"},{"fact_type":"auditor_change","fact_key":"17ac5f1f7e8231fea931da9f2db18d7e3ef2e90d","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2025-12-09T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"RSM US LLP","disagreement_text":null,"effective_date":"2025-12-08","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"Baker Tilly US, LLP"},"claim":"PETMED EXPRESS INC dismissed RSM US LLP as its auditor.","evidence_excerpt":"On the same date, the Company notified RSM US LLP (“RSM”) of its dismissal as the Company’s independent registered public accounting firm effective as of the completion of RSM’s interim review of the quarterly information on Form 10-Q as of and for the three-month periods ended June 30, 2025, and September 30, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001040130-25-000097","anchor_url":"https://secwatch.observer/filing/0001040130-25-000097#claim-17ac5f1f7e8231fea931da9f2db18d7e3ef2e90d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013025000097/0001040130-25-000097-index.htm"},{"fact_type":"auditor_change","fact_key":"2b26ef2404422f7f8ba139fad0457aab5fcbe857","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2025-12-09T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Baker Tilly US, LLP","disagreement_text":null,"effective_date":"2025-12-08","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"PETMED EXPRESS INC engaged Baker Tilly US, LLP as its auditor.","evidence_excerpt":"On December 8, 2025, the Audit Committee of the Board of Directors (the “Audit Committee”) of PetMed Express, Inc. (the “Company”), following a competitive process to determine the Company’s independent registered public accounting firm for the fiscal year ended March 31, 2026, approved the engagement of Baker Tilly US, LLP (“Baker Tilly”) to serve as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001040130-25-000097","anchor_url":"https://secwatch.observer/filing/0001040130-25-000097#claim-2b26ef2404422f7f8ba139fad0457aab5fcbe857","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013025000097/0001040130-25-000097-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"5cbcd351ea6ec467d2fe63e578adfdc6955c087b","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2025-11-13T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"plan_due","cure_deadline":"2025-12-29","deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2025-11-12","notice_type":"deficiency_notice","plan_due_date":"2025-11-28","raw_rule_text":null,"reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"PETMED EXPRESS INC received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"November 12, 2025, the Company received an expected notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), which indicated that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 (the “Q2 10-Q”), in addition to its continued delinquency in filing its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 (the “Q1 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires Nasdaq-listed companies to timely file all required periodic","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001040130-25-000086","anchor_url":"https://secwatch.observer/filing/0001040130-25-000086#claim-5cbcd351ea6ec467d2fe63e578adfdc6955c087b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013025000086/0001040130-25-000086-index.htm"},{"fact_type":"restructuring_charge","fact_key":"29ceaabd89b79282b7ae030d892ae05aeca96394","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2025-10-07T23:59:59+00:00","payload":{"affected_area":"PCRX trade name","charge_text":"$1.2 million","effective_date":"2025-10-01","event_type":"impairment","headcount_text":null,"item_codes_triggered":["2.06"]},"claim":"PETMED EXPRESS INC announced a impairment with charges of $1.2 million affecting PCRX trade name.","evidence_excerpt":"On October 1, 2025, the Audit Committee of the Board of Directors (the “Audit Committee”) of PetMed Express, Inc. (the “Company”), upon the recommendation of the Company’s management, concluded that a $1.2 million non-cash impairment of the Company’s PCRX trade name is required to be recorded in the quarter ended March 31, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001040130-25-000064","anchor_url":"https://secwatch.observer/filing/0001040130-25-000064#claim-29ceaabd89b79282b7ae030d892ae05aeca96394","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013025000064/0001040130-25-000064-index.htm"},{"fact_type":"auditor_change","fact_key":"1b79bbb0b71cb8d6e34eebd575dd4ed29a728667","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2025-10-07T23:59:59+00:00","payload":{"action":"non_reliance","auditor_name":"RSM US LLP","disagreement_text":null,"effective_date":"2025-10-01","item_codes_triggered":["4.02"],"non_reliance_signal":"non_reliance","successor_auditor_name":null},"claim":"PETMED EXPRESS INC reported that prior financial statements should not be relied upon.","evidence_excerpt":"The Audit Committee’s conclusion that the Affected Financials should no longer be relied upon","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001040130-25-000064","anchor_url":"https://secwatch.observer/filing/0001040130-25-000064#claim-1b79bbb0b71cb8d6e34eebd575dd4ed29a728667","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013025000064/0001040130-25-000064-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"5bef35a915e971f88296e3e9d72a6f51d7aa1224","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2025-08-25T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"plan_due","cure_deadline":null,"deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-08-20","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5250(c)(1)","reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"PETMED EXPRESS INC received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"August 20, 2025, PetMed Express, Inc. (the “ Company ”) received a notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”), which indicated that, as a result of the Company’s delay in filing its Annual Report on Form 10-K for its fiscal year ended March 31, 2025 (the “ Annual Report ”) and its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “ Quarterly Report ”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “ Listing Rule ”), which requires Nasdaq-listed companies to timely file all required periodic financial reports with the U.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001040130-25-000051","anchor_url":"https://secwatch.observer/filing/0001040130-25-000051#claim-5bef35a915e971f88296e3e9d72a6f51d7aa1224","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013025000051/0001040130-25-000051-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"15d05e935b3f39f3a6abc027a5e537ae573fb140","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2025-07-03T23:59:59+00:00","payload":{"company_response":"Company plans to file Form 10-K as soon as practicable","compliance_status":"plan_due","cure_deadline":"2025-12-29","deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2025-07-02","notice_type":"noncompliance_notice","plan_due_date":"2025-09-01","raw_rule_text":"Nasdaq Listing Rule 5250(c)(1)","reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"PETMED EXPRESS INC received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"July 2, 2025, the Company received an expected notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed the Form 10-K with the SEC, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires timely filing of all required periodic financial reports with the SEC. The Notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq. The Notice indicated that the Company must submit a plan to regain compliance with the Listing Rule within 60 calendar days","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001040130-25-000040","anchor_url":"https://secwatch.observer/filing/0001040130-25-000040#claim-15d05e935b3f39f3a6abc027a5e537ae573fb140","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013025000040/0001040130-25-000040-index.htm"},{"fact_type":"executive_change","fact_key":"ab97da468c","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2025-04-09T23:59:59+00:00","payload":{"action":"retire","action_category":"departure","departure_tone":"retirement","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Gian Fulgoni departed as Director at PETMED EXPRESS INC.","evidence_excerpt":"Dr. Gian Fulgoni, longtime Board member and former Chairman, has communicated his intention to retire from the Board when his term expires at the 2025 annual shareholders’ meeting.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001040130-25-000016","anchor_url":"https://secwatch.observer/filing/0001040130-25-000016#claim-ab97da468c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013025000016/0001040130-25-000016-index.htm"},{"fact_type":"executive_change","fact_key":"8938f340e4","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2025-04-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-04-09","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Peter Batushansky was appointed as Director at PETMED EXPRESS INC.","evidence_excerpt":"On April 9, 2025, the Board of Directors (the “Board”) of PetMed Express, Inc. (the “Company”) approved the appointment of Peter Batushansky to serve as a director of the Company beginning April 9, 2025.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001040130-25-000016","anchor_url":"https://secwatch.observer/filing/0001040130-25-000016#claim-8938f340e4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013025000016/0001040130-25-000016-index.htm"},{"fact_type":"executive_change","fact_key":"3add49b4db","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2024-09-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-09-16","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Robyn D'Elia was appointed as Chief Financial Officer at PETMED EXPRESS INC.","evidence_excerpt":"On September 11, 2024, the Board of Directors of PetMed Express, Inc. (“Company”) appointed Robyn D’Elia to serve as the Company’s Chief Financial Officer and to assume the duties of principal financial officer effective September 16, 2024 (“Effective Date”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001040130-24-000095","anchor_url":"https://secwatch.observer/filing/0001040130-24-000095#claim-3add49b4db","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013024000095/0001040130-24-000095-index.htm"},{"fact_type":"executive_change","fact_key":"cd54fc4661","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2024-08-05T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-08-19","interim":false,"role":"Chief Accounting Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Doug Krulik was appointed as Chief Accounting Officer at PETMED EXPRESS INC.","evidence_excerpt":"On August 2, 2024, the Board of Directors of PetMed Express, Inc. (“Company”) appointed Doug Krulik to serve as the Company’s Chief Accounting Officer to assume the duties of principal accounting officer and interim-principal financial officer effective August 19, 2024 (“Effective Date”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001040130-24-000062","anchor_url":"https://secwatch.observer/filing/0001040130-24-000062#claim-cd54fc4661","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013024000062/0001040130-24-000062-index.htm"},{"fact_type":"executive_change","fact_key":"037439285c","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2024-06-24T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-06-24","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Leah A. Solivan was appointed as director at PETMED EXPRESS INC.","evidence_excerpt":"On June 20, 2024, the Board of Directors (the “Board”) of PetMed Express, Inc. (the “Company”) approved the appointment of Leah A. Solivan to serve as a director of the Company beginning June 24, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001040130-24-000048","anchor_url":"https://secwatch.observer/filing/0001040130-24-000048#claim-037439285c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013024000048/0001040130-24-000048-index.htm"},{"fact_type":"executive_change","fact_key":"56c62db5d7","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2024-05-31T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Chief Financial Officer, Treasurer, and Secretary","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Christine Chambers resigned as Chief Financial Officer, Treasurer, and Secretary at PETMED EXPRESS INC.","evidence_excerpt":"On May 31, 2024, PetMed Express, Inc. (the “Company”) entered into a Transition and Separation Agreement (the “Agreement”) with Christine Chambers, the Company’s Chief Financial Officer, Treasurer, and Secretary, pursuant to which the Company and Ms. Chambers agreed to the mutual termination of Ms. Chambers’ employment with the Company following a transition period.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001040130-24-000032","anchor_url":"https://secwatch.observer/filing/0001040130-24-000032#claim-56c62db5d7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013024000032/0001040130-24-000032-index.htm"},{"fact_type":"executive_change","fact_key":"13e6a35bcc","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2024-05-20T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-06-03","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Justin L. Mennen was appointed as Director at PETMED EXPRESS INC.","evidence_excerpt":"On May 16, 2024, the Board of Directors (the “Board”) of PetMed Express, Inc. (the “Company”), appointed Justin L. Mennen to serve as a director of the Company beginning June 3, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001040130-24-000028","anchor_url":"https://secwatch.observer/filing/0001040130-24-000028#claim-13e6a35bcc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013024000028/0001040130-24-000028-index.htm"},{"fact_type":"executive_change","fact_key":"9f924c8714","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2024-04-29T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-04-29","interim":false,"role":"Chief Executive Officer and President","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Sandra Campos was appointed as Chief Executive Officer and President at PETMED EXPRESS INC.","evidence_excerpt":"the Company appointed Sandra Campos, an existing director of the Company, as the Company’s new Chief Executive Officer and President.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001040130-24-000022","anchor_url":"https://secwatch.observer/filing/0001040130-24-000022#claim-9f924c8714","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013024000022/0001040130-24-000022-index.htm"},{"fact_type":"executive_change","fact_key":"c81d876bbf","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2024-04-29T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-04-29","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"Sandra Campos","successor_named":true},"claim":"Mathew Hulett resigned as President and Chief Executive Officer at PETMED EXPRESS INC.","evidence_excerpt":"Mr. Hulett resigned as President and Chief Executive Officer, and also as a director, of the Company effective April 29, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001040130-24-000022","anchor_url":"https://secwatch.observer/filing/0001040130-24-000022#claim-c81d876bbf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013024000022/0001040130-24-000022-index.htm"},{"fact_type":"earnings_release","fact_key":"b245d511138c728841bf8137b6a6ffdbe249aa85","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2024-04-15T23:59:59+00:00","payload":{"eps_text":"$(0.10) per diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the quarter ended December 31, 2023 was $2.0 million","period_text":"fiscal third quarter 2024","report_date":"2024-04-15","result_type":"reported_results","revenue_text":"Net sales for the quarter ended December 31, 2023, were $65.3 million"},"claim":"PETMED EXPRESS INC reported fiscal third quarter 2024 results: revenue Net sales for the quarter ended December 31, 2023, were $65.3 million, net income Net loss for the quarter ended December 31, 2023 was $2.0 million, EPS $(0.10) per diluted share.","evidence_excerpt":"Net sales for the quarter ended December 31, 2023, were $65.3 million, compared to $58.9 million for the third quarter in the prior year, an increase of 11% year over year.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001040130-24-000020","anchor_url":"https://secwatch.observer/filing/0001040130-24-000020#claim-b245d511138c728841bf8137b6a6ffdbe249aa85","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013024000020/0001040130-24-000020-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"f22206e34b476c6606e9e6848c142889642c1212","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2024-02-15T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"plan_due","cure_deadline":"2024-08-07","deficiency_type":"late_filing","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2024-02-13","notice_type":"noncompliance_notice","plan_due_date":"2024-04-13","raw_rule_text":"Nasdaq Listing Rule 5250(c)(1)","reported_value":null,"rule_numbers":["5250(c)(1)"],"rules_cited_in_text":true},"claim":"PETMED EXPRESS INC received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"February 13, 2024, the Company received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed the Form 10-Q with the SEC, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires timely filing of all required periodic financial reports with the SEC. The Notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq. The Notice indicated that the Company must submit a plan to regain compliance with the Listing Rule within 60 calendar days and","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001040130-24-000010","anchor_url":"https://secwatch.observer/filing/0001040130-24-000010#claim-f22206e34b476c6606e9e6848c142889642c1212","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013024000010/0001040130-24-000010-index.htm"},{"fact_type":"earnings_release","fact_key":"28ba99bc94719b504096bb2cd85c7d98835cee77","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2024-02-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"fiscal quarter ended December 31, 2023","report_date":"2024-02-08","result_type":"preliminary_results","revenue_text":"$65.3 million"},"claim":"PETMED EXPRESS INC reported fiscal quarter ended December 31, 2023 results: revenue $65.3 million.","evidence_excerpt":"Net sales for the quarter ended December 31, 2023, are expected to be $65.3 million","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001040130-24-000004","anchor_url":"https://secwatch.observer/filing/0001040130-24-000004#claim-28ba99bc94719b504096bb2cd85c7d98835cee77","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013024000004/0001040130-24-000004-index.htm"},{"fact_type":"auditor_change","fact_key":"0ef05adda08c7905d4b65018feab368ed25da8da","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2024-02-08T23:59:59+00:00","payload":{"action":"non_reliance","auditor_name":"RSM US LLP","disagreement_text":null,"effective_date":"2024-02-07","item_codes_triggered":["4.02"],"non_reliance_signal":"restatement","successor_auditor_name":null},"claim":"PETMED EXPRESS INC reported that prior financial statements should not be relied upon.","evidence_excerpt":"” and together with the Q1 2024 Quarterly Report, the 2023 Annual Report and the Historical Quarterly Reports, the “Reports” and all financial statements included in the Reports, collectively the “Affected Financials”), should no longer be relied upon. As a result of the foregoing determined, related press releases, shareholder communications, investor presentations or other communications describing relevant portions of the Affected Financials should no longer be relied upon. The Audit Committee’s conclusion was based on management’s determination that the Company (1) misapplied generally accepted accounting principles relating to certain accruals for sales tax liabilities resulting from sales of the Company’s products and services to its customers and (2) incorrectly valued the deferred tax asset acquired in connection with the Company’s acquisition of PetCareRx in April 2023, in each","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001040130-24-000004","anchor_url":"https://secwatch.observer/filing/0001040130-24-000004#claim-0ef05adda08c7905d4b65018feab368ed25da8da","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013024000004/0001040130-24-000004-index.htm"},{"fact_type":"earnings_release","fact_key":"7c786ff5ac5c02df8c4920927df777a43fbc3d27","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2023-10-30T23:59:59+00:00","payload":{"eps_text":"$(0.00) per diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the quarter ended September 30, 2023 was $70 thousand, or $(0.00) per diluted share","period_text":"its second quarter ended September 30, 2023","report_date":"2023-10-30","result_type":"reported_results","revenue_text":"$71.0 million"},"claim":"PETMED EXPRESS INC reported its second quarter ended September 30, 2023 results: revenue $71.0 million, net income Net loss for the quarter ended September 30, 2023 was $70 thousand, or $(0.00) per diluted share, EPS $(0.00) per diluted share.","evidence_excerpt":"TM , today announced its financial results for its second quarter ended September 30, 2023. Quarterly Highlights • Net sales for the quarter ended September 30, 2023, were $71.0 million, compared to $65.4 million for the second quarter in the prior year, an increase of 9% year over year. The current quarter includes the results from the recent acquisition of","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001040130-23-000078","anchor_url":"https://secwatch.observer/filing/0001040130-23-000078#claim-7c786ff5ac5c02df8c4920927df777a43fbc3d27","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013023000078/0001040130-23-000078-index.htm"},{"fact_type":"shareholder_vote","fact_key":"b9e65369728539c8ca43959a87f7b2f69e131597","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2023-08-04T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-03","outcome":"passed","proposal_text":"Ratification of appointment of RMS US LLP as independent registered public accounting firm for fiscal year 2024","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"69,806","votes_against":"152,734","votes_for":"16,763,924","votes_withheld":null}]},"claim":"PETMED EXPRESS INC shareholders approved Ratification of appointment of RMS US LLP as independent registered public accounting firm for fiscal year 2024 at the 2023-08-03 meeting.","evidence_excerpt":"Proposal 4 - The Company’s shareholders ratified the appointment of RMS US LLP as the Company’s independent registered public accounting firm for fiscal year 2024 by the following final voting results:","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001040130-23-000062","anchor_url":"https://secwatch.observer/filing/0001040130-23-000062#claim-b9e65369728539c8ca43959a87f7b2f69e131597","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013023000062/0001040130-23-000062-index.htm"},{"fact_type":"shareholder_vote","fact_key":"d482c8f2e09442da672292265c990f41d2ded5de","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2023-08-04T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-03","outcome":"passed","proposal_text":"Advisory vote on frequency of future advisory votes on named executive officer compensation","proposal_type":"say_on_pay_frequency","results":[{"broker_non_votes":"4,278,231","subject":null,"votes_abstain":null,"votes_against":"103,085","votes_for":"12,327,290","votes_withheld":"230,599"}]},"claim":"PETMED EXPRESS INC shareholders approved Advisory vote on frequency of future advisory votes on named executive officer compensation at the 2023-08-03 meeting.","evidence_excerpt":"Proposal 3 - The Company’s shareholders recommended, on an advisory basis, a frequency of every year for future advisory votes on named executive officer compensation by the following final voting results:","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001040130-23-000062","anchor_url":"https://secwatch.observer/filing/0001040130-23-000062#claim-d482c8f2e09442da672292265c990f41d2ded5de","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013023000062/0001040130-23-000062-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3e1fe78ed1b7aebfc46f1c61044c6f44398aa535","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2023-08-04T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-03","outcome":"passed","proposal_text":"Advisory vote on compensation of named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"4,278,229","subject":null,"votes_abstain":"481,316","votes_against":"1,043,623","votes_for":"11,183,296","votes_withheld":null}]},"claim":"PETMED EXPRESS INC shareholders approved Advisory vote on compensation of named executive officers at the 2023-08-03 meeting.","evidence_excerpt":"Proposal 2 - The Company’s shareholders approved, on an advisory basis, the compensation of the Company’s named executive officers named in the Proxy Statement by the following final voting results:","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001040130-23-000062","anchor_url":"https://secwatch.observer/filing/0001040130-23-000062#claim-3e1fe78ed1b7aebfc46f1c61044c6f44398aa535","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013023000062/0001040130-23-000062-index.htm"},{"fact_type":"shareholder_vote","fact_key":"9bd3e91c20cf98e5e4f675a34dff19b12a9cc375","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2023-08-04T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-08-03","outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"4,278,226","subject":"Leslie C.G. Campbell","votes_abstain":"44,845","votes_against":"1,273,818","votes_for":"11,389,575","votes_withheld":null},{"broker_non_votes":"4,278,227","subject":"Sandra Y. Campos","votes_abstain":"30,919","votes_against":"786,763","votes_for":"11,890,555","votes_withheld":null},{"broker_non_votes":"4,278,227","subject":"Gian M. Fulgoni","votes_abstain":"53,489","votes_against":"1,764,442","votes_for":"10,890,306","votes_withheld":null},{"broker_non_votes":"4,278,227","subject":"Mathew N. Hulett","votes_abstain":"29,946","votes_against":"813,903","votes_for":"11,864,388","votes_withheld":null},{"broker_non_votes":"4,278,227","subject":"Diana Garvis Purcel","votes_abstain":"32,786","votes_against":"1,027,188","votes_for":"11,648,263","votes_withheld":null}]},"claim":"PETMED EXPRESS INC shareholders approved Election of Directors at the 2023-08-03 meeting.","evidence_excerpt":"Proposal 1 - The five director nominees proposed by the Company’s Board of Directors (“Board”) were elected to serve as members of the Board until the next annual meeting of shareholders and until their respective successors have been duly elected and qualified by the following final voting results:","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001040130-23-000062","anchor_url":"https://secwatch.observer/filing/0001040130-23-000062#claim-9bd3e91c20cf98e5e4f675a34dff19b12a9cc375","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013023000062/0001040130-23-000062-index.htm"},{"fact_type":"earnings_release","fact_key":"44f6a49e004f9c4d5c54bdae13513352debe50ed","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2023-07-31T23:59:59+00:00","payload":{"eps_text":"$(0.04) per diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the quarter ended June 30, 2023 was $(0.9) million","period_text":"first quarter ended June 30, 2023","report_date":"2023-07-31","result_type":"reported_results","revenue_text":"$78.2 million"},"claim":"PETMED EXPRESS INC reported first quarter ended June 30, 2023 results: revenue $78.2 million, net income Net loss for the quarter ended June 30, 2023 was $(0.9) million, EPS $(0.04) per diluted share.","evidence_excerpt":"Health Expert TM , today announced its financial results for its first quarter ended June 30, 2023. Quarterly Highlights • Net sales for the quarter ended June 30, 2023, were $78.2 million, compared to $70.2 million for the first quarter in the prior year, an increase of 11.5%. • PetMeds reported an increase in new customers of 25% year over year for the quarter","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001040130-23-000049","anchor_url":"https://secwatch.observer/filing/0001040130-23-000049#claim-44f6a49e004f9c4d5c54bdae13513352debe50ed","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013023000049/0001040130-23-000049-index.htm"},{"fact_type":"earnings_release","fact_key":"f1977c501aab2f5f9670769ac14f6ac1335467a2","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2023-05-26T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and year ended on March 31, 2023","report_date":"2023-05-22","result_type":"reported_results","revenue_text":null},"claim":"PETMED EXPRESS INC reported financial results for the fourth quarter and year ended on March 31, 2023.","evidence_excerpt":"On May 22, 2023, PetMed Express, Inc. (the “Company”) held a conference call to discuss its financial results for the fourth quarter and year ended on March 31, 2023.","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001040130-23-000036","anchor_url":"https://secwatch.observer/filing/0001040130-23-000036#claim-f1977c501aab2f5f9670769ac14f6ac1335467a2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013023000036/0001040130-23-000036-index.htm"},{"fact_type":"earnings_release","fact_key":"0e979a973b9cab956c019c9464da7e2dda3a9ca3","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2023-05-22T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"fourth quarter and fiscal year ended March 31, 2023","report_date":"2023-05-22","result_type":"reported_results","revenue_text":null},"claim":"PETMED EXPRESS INC reported financial results for fourth quarter and fiscal year ended March 31, 2023.","evidence_excerpt":"On May 22, 2023, PetMed Express, Inc. (the “Company”) issued a press release announcing its March 31, 2023 fourth quarter financial results and other financial information","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001040130-23-000027","anchor_url":"https://secwatch.observer/filing/0001040130-23-000027#claim-0e979a973b9cab956c019c9464da7e2dda3a9ca3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013023000027/0001040130-23-000027-index.htm"},{"fact_type":"executive_change","fact_key":"c583a5e215","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2023-05-19T23:59:59+00:00","payload":{"action":"not stand for re-election","action_category":"departure","departure_tone":"routine","effective_date":"2023-08-03","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Jodi Watson departed as Director at PETMED EXPRESS INC.","evidence_excerpt":"On May 16, 2023, Jodi Watson informed the Board that she does not wish to stand for re-election to the Board when her term expires at the Company's 2023 Annual Meeting of Shareholders on August 3, 2023","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001040130-23-000023","anchor_url":"https://secwatch.observer/filing/0001040130-23-000023#claim-c583a5e215","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013023000023/0001040130-23-000023-index.htm"},{"fact_type":"executive_change","fact_key":"9f4843f929","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2023-05-19T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-05-17","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Sandra Y. Campos was appointed as Director at PETMED EXPRESS INC.","evidence_excerpt":"On May 17, 2023, the Board of Directors (\"Board\") of PetMed Express, Inc. (the \"Company\") approved the appointment of Sandra Y. Campos as a director on its Board","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001040130-23-000023","anchor_url":"https://secwatch.observer/filing/0001040130-23-000023#claim-9f4843f929","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013023000023/0001040130-23-000023-index.htm"},{"fact_type":"earnings_release","fact_key":"791e2e1b9bf8e2e8e25e65e0239338a35e9ab5c2","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2023-02-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"quarter ended December 31, 2022","report_date":"2023-02-06","result_type":"reported_results","revenue_text":null},"claim":"PETMED EXPRESS INC reported financial results for quarter ended December 31, 2022.","evidence_excerpt":"On February 6, 2023, PetMed Express, Inc. (the “Company”) held a conference call to discuss its financial results for the quarter ended on December 31, 2022.","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001040130-23-000015","anchor_url":"https://secwatch.observer/filing/0001040130-23-000015#claim-791e2e1b9bf8e2e8e25e65e0239338a35e9ab5c2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013023000015/0001040130-23-000015-index.htm"},{"fact_type":"earnings_release","fact_key":"e01425275443a9eb38875ff3e796e54649c99b8e","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2023-02-06T23:59:59+00:00","payload":{"eps_text":"$(0.00) diluted earnings per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$19.0 thousand","period_text":"third quarter ended December 31, 2022","report_date":"2023-02-06","result_type":"reported_results","revenue_text":"$58.9 million"},"claim":"PETMED EXPRESS INC reported third quarter ended December 31, 2022 results: revenue $58.9 million, net income $19.0 thousand, EPS $(0.00) diluted earnings per share.","evidence_excerpt":"Expert TM , today announced its financial results for its third quarter ended December 31, 2022. Quarterly Highlights • Net sales for the quarter ended December 31, 2022, were $58.9 million, compared to $60.7 million for third quarter in the prior year, a decrease of 3.0%. • PetMeds® reports new customers increased 9% year over year for the quarter ended December","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001040130-23-000011","anchor_url":"https://secwatch.observer/filing/0001040130-23-000011#claim-e01425275443a9eb38875ff3e796e54649c99b8e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013023000011/0001040130-23-000011-index.htm"},{"fact_type":"material_agreement","fact_key":"d72620e2b6162fe50405f35fdbb3d45d80204d06","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2023-01-17T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Merger Agreement","agreement_type":"merger","counterparty":"PetCareRx, Inc.","effective_date":"2023-01-13","item_codes_triggered":["1.01"],"value_text":"$36 million in cash"},"claim":"PETMED EXPRESS INC entered into Merger Agreement with PetCareRx, Inc. valued at $36 million in cash (effective 2023-01-13).","evidence_excerpt":"On January 13, 2023, PetMed Express, Inc. (the “ Company ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Harry Merger Sub, Inc., a New York corporation and a wholly-owned subsidiary of the Company (“ Merger Sub ”), PetCareRx, Inc., a New York corporation (“ PetCareRx ”), and Jeanette Loeb (as representative of the PetCareRx equity holders).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001040130-23-000003","anchor_url":"https://secwatch.observer/filing/0001040130-23-000003#claim-d72620e2b6162fe50405f35fdbb3d45d80204d06","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013023000003/0001040130-23-000003-index.htm"},{"fact_type":"earnings_release","fact_key":"49c7f30579d5a2b8ad28bf82d5d9f47a8e9dfd74","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2022-11-07T23:59:59+00:00","payload":{"eps_text":"$0.13 diluted earnings per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$2.6 million","period_text":"second quarter ended September 30, 2022","report_date":"2022-11-07","result_type":"reported_results","revenue_text":"$65.4 million"},"claim":"PETMED EXPRESS INC reported second quarter ended September 30, 2022 results: revenue $65.4 million, net income $2.6 million, EPS $0.13 diluted earnings per share.","evidence_excerpt":"Net sales for the quarter ended September 30, 2022, were $65.4 million, compared to $67.4 million for second quarter in the prior year, a decrease of 3.0%.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001040130-22-000006","anchor_url":"https://secwatch.observer/filing/0001040130-22-000006#claim-49c7f30579d5a2b8ad28bf82d5d9f47a8e9dfd74","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000104013022000006/0001040130-22-000006-index.htm"},{"fact_type":"executive_change","fact_key":"4e96865a8f","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2022-08-03T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-08-03","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Christine Chambers was appointed as Chief Financial Officer at PETMED EXPRESS INC.","evidence_excerpt":"On August 3, 2022, PetMed Express, Inc. (the “Company”) entered into an employment agreement (“Employment Agreement”) with Christine Chambers to set forth the terms and conditions of Ms. Chambers’ employment as Chief Financial Officer of the Company.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001437749-22-018636","anchor_url":"https://secwatch.observer/filing/0001437749-22-018636#claim-4e96865a8f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000143774922018636/0001437749-22-018636-index.htm"},{"fact_type":"executive_change","fact_key":"b44134a6db","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2022-07-14T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-08-03","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Christine Chambers was appointed as Chief Financial Officer at PETMED EXPRESS INC.","evidence_excerpt":"On July 14, 2022, the Board of Directors of PetMed Express, Inc. (“Company”) appointed Christine Chambers to serve as the Company’s Chief Financial Officer to assume the duties of principal financial officer and principal accounting officer effective August 3, 2022 (“Effective Date”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-22-017145","anchor_url":"https://secwatch.observer/filing/0001437749-22-017145#claim-b44134a6db","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000143774922017145/0001437749-22-017145-index.htm"},{"fact_type":"executive_change","fact_key":"9a55e6702a","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2022-03-28T23:59:59+00:00","payload":{"action":"intends to retire","action_category":"departure","departure_tone":"retirement","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ronald J. Korn departed as Director at PETMED EXPRESS INC.","evidence_excerpt":"Ronald J. Korn notified the Board that he intends to retire as a director of the Company at the end of his current term and does not wish to seek reelection at our 2022 Annual Meeting of Stockholders","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-22-007323","anchor_url":"https://secwatch.observer/filing/0001437749-22-007323#claim-9a55e6702a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000143774922007323/0001437749-22-007323-index.htm"},{"fact_type":"executive_change","fact_key":"0de335674e","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2022-03-28T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-04-04","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Diana Garvis Purcel was appointed as Director at PETMED EXPRESS INC.","evidence_excerpt":"the Board of Directors (“Board”) of PetMed Express, Inc. (the “Company”) approved the appointment of Diana Garvis Purcel as a director on our Board","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-22-007323","anchor_url":"https://secwatch.observer/filing/0001437749-22-007323#claim-0de335674e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000143774922007323/0001437749-22-007323-index.htm"},{"fact_type":"executive_change","fact_key":"c62a771362","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2021-08-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-08-30","interim":false,"role":"Board member","role_category":"director","successor_name":null,"successor_named":false},"claim":"Mathew N. Hulett was appointed as Board member at PETMED EXPRESS INC.","evidence_excerpt":"On August 25, 2021, the Board of Directors (“Board”) of PetMed Express, Inc. (the “Company”) appointed Mathew N. Hulett, age 51, as Chief Executive Officer and President of the Company and as a Board member.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-21-021120","anchor_url":"https://secwatch.observer/filing/0001437749-21-021120#claim-c62a771362","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000143774921021120/0001437749-21-021120-index.htm"},{"fact_type":"executive_change","fact_key":"6a9158dc59","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2021-08-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-08-30","interim":false,"role":"Chief Executive Officer and President","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Mathew N. Hulett was appointed as Chief Executive Officer and President at PETMED EXPRESS INC.","evidence_excerpt":"On August 25, 2021, the Board of Directors (“Board”) of PetMed Express, Inc. (the “Company”) appointed Mathew N. Hulett, age 51, as Chief Executive Officer and President of the Company and as a Board member.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-21-021120","anchor_url":"https://secwatch.observer/filing/0001437749-21-021120#claim-6a9158dc59","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000143774921021120/0001437749-21-021120-index.htm"},{"fact_type":"executive_change","fact_key":"80f1daafd0","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2021-07-06T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-07-31","interim":true,"role":"Interim Chief Executive Officer and President","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Bruce S. Rosenbloom was appointed as Interim Chief Executive Officer and President at PETMED EXPRESS INC.","evidence_excerpt":"the Board appointed Bruce S. Rosenbloom, the Company’s Chief Financial Officer, as Interim Chief Executive Officer (principal executive officer) and President of the Company, effective upon Mr. Akdag’s departure","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-21-016414","anchor_url":"https://secwatch.observer/filing/0001437749-21-016414#claim-80f1daafd0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000143774921016414/0001437749-21-016414-index.htm"},{"fact_type":"executive_change","fact_key":"aae02c04bd","cik":1040130,"ticker":"PETS","company_name":"PETMED EXPRESS INC","filed_at":"2021-07-06T23:59:59+00:00","payload":{"action":"not extended","action_category":"departure","departure_tone":"routine","effective_date":"2021-07-30","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"Bruce S. Rosenbloom","successor_named":true},"claim":"Menderes Akdag departed as President and Chief Executive Officer at PETMED EXPRESS INC.","evidence_excerpt":"the Company will not extend Mr. Akdag’s employment agreement with the Company and that the employment agreement would therefore end on July 30, 2021","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-21-016414","anchor_url":"https://secwatch.observer/filing/0001437749-21-016414#claim-aae02c04bd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1040130/000143774921016414/0001437749-21-016414-index.htm"}]}